Drug therapy for amyotrophic lateral sclerosis: Where are we now?

被引：0

作者：

Carter, GT ^{[1
]}

Krivickas, LS

Weydt, P

Weiss, MD

Miller, RG

机构：

[1] Univ Washington, Sch Med, Muscular Dystrophy Assoc Amyotroph Lateral Sclero, Seattle, WA 98195 USA

[2] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA

[3] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA

[4] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA

[5] Harvard Univ, Sch Med, Boston, MA 02114 USA

[6] Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA 94115 USA

来源：

IDRUGS | 2003年 / 6卷 / 02期

关键词：

amyotrophic lateral sclerosis; clinical trials; motor neuron disease; neurotrophic growth factors; riluzole;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the 60 years since Lou Gehrig died from amyotrophic lateral sclerosis (ALS) there have been numerous advances in our understanding of this disease. However, scant progress has been made regarding disease-altering treatments. Today most physicians still recommend vitamin E, which is the treatment Gehrig himself received. In this paper we will review what is currently known about the pathophysiology of ALS as well as the history of clinical trials in ALS. We indicate current and future directions in research and clinical trials, and also argue that a logical next step for clinical trials in ALS should be combination drug treatment.

引用

页码：147 / 153

页数：7

共 50 条

[1] Amyotrophic lateral sclerosis: where are we now?
Miller, R
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 1998, : 3 - 5
[2] Drug Therapy in Amyotrophic Lateral Sclerosis
Distad, B. Jane
Meekins, Gregg D.
Liou, Lee L.
Weiss, Michael D.
Carter, Gregory T.
Miller, Robert G.
[J]. PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA, 2008, 19 (03) : 633 - +
[3] Amyotrophic lateral sclerosis and palliative care: Where we are, and the road ahead
Blackhall, Leslie J.
[J]. MUSCLE & NERVE, 2012, 45 (03) : 311 - 318
[4] Voice-Based Classification of Amyotrophic Lateral Sclerosis: Where Are We and Where Are We Going? A Systematic Review
Vieira, Helder
Costa, Nelson
Sousa, Tomas
Reis, Sara
Coelho, Luis
[J]. NEURODEGENERATIVE DISEASES, 2020, 19 (5-6) : 163 - 170
[5] Amyotrophic Lateral Sclerosis: Drug Therapy from the Bench to the Bedside
Gibson, Summer Bell
Bromberg, Mark B.
[J]. SEMINARS IN NEUROLOGY, 2012, 32 (03) : 173 - 178
[6] Where and Why Modeling Amyotrophic Lateral Sclerosis
Liguori, Francesco
Amadio, Susanna
Volonte, Cinzia
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
[7] DNA methylation in amyotrophic lateral sclerosis: where do we stand and what is next?
Coppede, Fabio
[J]. EPIGENOMICS, 2024,
[8] Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?
Henriques, Alexandre
Pitzer, Claudia
Schneider, Armin
[J]. FRONTIERS IN NEUROSCIENCE, 2010, 4
[9] Drug targeting: Where are we now and where are we going?
Duncan, R
[J]. JOURNAL OF DRUG TARGETING, 1997, 5 (01) : 1 - 4
[10] Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease
Brettschneider, Johannes
Kurent, Jerome
Ludolph, Albert
Mitchell, J. Douglas
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (03):

← 1 2 3 4 5 →